High-throughput in vitro assays
with dry AMD pathophysiology key features

Learn more with our webinar
on Phenocell's human iPSC-derived Retinal Pigment Epithelium AMD model

Dry AMD Platform webinar

Improve the relevance and reproducibility of your R&D

If you missed our Dry AMD webinar, register here to get a one-to-one presentation

Thank you! Your submission has been received!

Oops! Something went wrong while submitting the form.

High-throughput platform

Our high-content screening assays can test a large number of compounds in 96wp format.
Identify the most promising compounds before further downstream studies.

In vitro model that recapitulates key features of dry AMD pathophysiology, with a screenable endpoint (Live/dead cells in 96wp).
Full phenotypic, molecular and functional characteristics of in situ RPE

Blue light exposure

Use our iPSC-derived in vitro model assay
to improve the relevance of
your ophthalmology dry AMD R&D

High-throughput in vitro assays with dry AMD pathophysiology key features

Learn more with our webinar on Phenocell's human iPSC-derived Retinal Pigment Epithelium AMD model

Schedule a one-to-one presentation:

High-throughput platform

Blue light exposure

High-throughput in vitro assays
with dry AMD pathophysiology key features

Learn more with our webinar
on Phenocell's human iPSC-derived Retinal Pigment Epithelium AMD model